{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-055368","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.891191+00:00","generated_at":"2026-06-03T03:31:47.290290+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Applied DNA provides investor presentation with no new material disclosures","bullets":["Company filed a presentation for investor use; no financial results or guidance included.","Presentation emphasizes cell-free enzymatic DNA platform for genetic medicines.","No specific data on revenue, contracts, or milestones disclosed in the filing.","Risks highlighted include history of net losses and going concern doubt."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-055368","json":"https://secwatch.observer/filing/0001104659-24-055368.json","markdown":"https://secwatch.observer/filing/0001104659-24-055368.md","text":"https://secwatch.observer/filing/0001104659-24-055368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465924055368/0001104659-24-055368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465924055368/tm2413220d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:31:47.290290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}